Search research articles
Contact Us
Filters
Showing results (41-50 of 58) with videos related to
Page
of 6
Sort By:
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
October 25, 2014
Electroencephalographic theta activity and cognition in schizophrenia: preliminary results
Adam Wichniak, Łukasz Okruszek, Magdalena Linke, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 26, 2012
Treatment of depression in first episode of schizophrenia: results from EUFEST
Janusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, et al.
Psychiatry Research
|
December 9, 2014
Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?
Magdalena Linke, Konrad S Jankowski, Agnieszka Ciołkiewicz, et al.
Pharmacological Reports : PR
|
May 3, 2015
Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype
Przemyslaw Bienkowski, Jerzy Samochowiec, Justyna Pelka-Wysiecka, et al.
The Journal of Clinical Psychiatry
|
February 27, 2014
Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study
Dan J Stein, Antti Ahokas, Miguel S Márquez, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
July 28, 2015
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology
Florence Thibaut, Nash N Boutros, Marek Jarema, et al.
The Psychiatric Quarterly
|
January 21, 2015
The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties
Małgorzata Jędrasik-Styła, Agnieszka Ciołkiewicz, Rafał Styła, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 17, 2017
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
Dan J Stein, Antti Ahokas, Marek Jarema, et al.
The International Journal of Social Psychiatry
|
October 10, 2014
Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: The FEDORA project
Elizabeth A Corker, Alina Beldie, Cecilia Brain, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 24, 2018
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
Dan J Stein, Jon-Paul Khoo, Antti Ahokas, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 58) with videos related to
Sort By:
Page
of 6
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
October 25, 2014
Electroencephalographic theta activity and cognition in schizophrenia: preliminary results
Adam Wichniak, Łukasz Okruszek, Magdalena Linke, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
May 26, 2012
Treatment of depression in first episode of schizophrenia: results from EUFEST
Janusz K Rybakowski, Kristof Vansteelandt, Tomasz Szafranski, et al.
Psychiatry Research
|
December 9, 2014
Age or age at onset? Which of them really matters for neuro and social cognition in schizophrenia?
Magdalena Linke, Konrad S Jankowski, Agnieszka Ciołkiewicz, et al.
Pharmacological Reports : PR
|
May 3, 2015
Functional polymorphism of matrix metalloproteinase-9 (MMP9) gene is not associated with schizophrenia and with its deficit subtype
Przemyslaw Bienkowski, Jerzy Samochowiec, Justyna Pelka-Wysiecka, et al.
The Journal of Clinical Psychiatry
|
February 27, 2014
Agomelatine in generalized anxiety disorder: an active comparator and placebo-controlled study
Dan J Stein, Antti Ahokas, Miguel S Márquez, et al.
The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry
|
July 28, 2015
Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia part I: Neurophysiology
Florence Thibaut, Nash N Boutros, Marek Jarema, et al.
The Psychiatric Quarterly
|
January 21, 2015
The Polish Academic Version of the MATRICS Consensus Cognitive Battery (MCCB): Evaluation of Psychometric Properties
Małgorzata Jędrasik-Styła, Agnieszka Ciołkiewicz, Rafał Styła, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
March 17, 2017
Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study
Dan J Stein, Antti Ahokas, Marek Jarema, et al.
The International Journal of Social Psychiatry
|
October 10, 2014
Experience of stigma and discrimination reported by people experiencing the first episode of schizophrenia and those with a first episode of depression: The FEDORA project
Elizabeth A Corker, Alina Beldie, Cecilia Brain, et al.
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
August 24, 2018
12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25-50 mg/day) versus escitalopram (10-20 mg/day) in out-patients with severe generalized anxiety disorder
Dan J Stein, Jon-Paul Khoo, Antti Ahokas, et al.
Page
of 6